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PERSPECTIVE
G protein-coupled receptor 37 
(GPR37) emerges as an important 
modulator of adenosinergic 
transmission in the striatum
G protein-coupled receptor 37 (GPR37), also known as parkin 
associated endothelin-like (Pael) receptor, is an orphan G pro-
tein-coupled receptor, which suffers a defective parking ubiq-
uitination in autosomal recessive Parkinson’s disease promoting 
its endoplasmic reticulum aggregation and stress, neurotoxicity 
and neuronal death (Takahashi and Imai, 2003). Interestingly, 
we have demonstrated previously that GPR37 heteromerizes 
with adenosine A2A receptor (A2AR) in the striatum (Morató 
et al., 2017; Sokolina et al., 2017). In addition, we also report-
ed some functional consequences of this direct interaction, 
whereby GPR37 deletion enhanced striatal A2AR cell surface 
expression with a concomitant increase in A2AR agonist-me-
diated cAMP accumulation (Morató et al., 2017); accordingly, 
an enhancement of A2AR agonist-induced catalepsy and antag-
onist-induced locomotor activity was observed upon GPR37 
deletion (Morató et al., 2017). Overall, it has been hypothesized 
that GPR37 might hold a chaperone-like activity controlling 
A2AR cell surface targeting and function. However, the precise 
physiological function of GPR37 still is unidentified. The cur-
rent findings now provide additional evidence for the role of 
GPR37 as a repressor of A2AR function. Thus, while chronic 
A2AR antagonist treatment (i.e., SCH58261, 1 mg/kg per day, 
intraperitoneal administration, 10 days) of mice lacking GPR37 
did not affect the striatum-dependent cued learning, it en-
hanced locomotor sensitization (Morató et al., 2019). Moreover, 
chronic A2AR blockade boosted striatal long-term depression 
(LTD) in corticostriatal synapses of GPR37-/- but not of wild 
type mice; this observation correlated well with the adenosin-
ergic neurochemical modifications present in GPR37-/- mice, 
namely an increased density of A2AR and decreased levels of 
adenosine (Morató et al., 2019). Overall, GPR37 emerged as key 
contestant controlling A2AR function particularly upon chronic 
A2AR blockade, thus delineating A2AR-dependent long-term 
plastic changes in corticostriatal synapses.  
Adenosine is an key neuromodulator in the central nervous 
system regulating two important brain processes, namely 
neurotransmission and neural metabolism. Indeed, adenosine 
modulates the basal levels and release of many neurotransmit-
ters including glutamate, γ-aminobutyric acid (GABA), dopa-
mine and serotonin, thus fine-tuning synaptic transmission. 
Derived from the breakdown of intra- and extracellular adenos-
ine triphosphate, adenosine is released upon some physiolog-
ical and pathological stimuli, thus exerting its effects through 
four G protein-coupled adenosine receptors. In the brain, the 
density of A2AR is far greater in regions heavily innervated 
by dopaminergic terminals, namely in the striatum, nucleus 
accumbens and olfactory tubercle. Interestingly, the striatum 
is a large forebrain region involved in action initiation, mo-
tor skill learning and development and cued action-selection 
memory. Moreover, this structure could be involved both in 
reward-association memory and visual recognition memory. In 
Parkinson’s disease, a progressive degeneration of midbrain do-
pamine neurons is associated with an aberrant striatal activity 
producing marked motor impairments, including bradykinesia, 
tremor, and rigidity. Indeed, dopamine replacement therapy 
with levodopa is the “gold standard” Parkinson’s disease treat-
ment. While initially effective in treating motor deficits, most 
Parkinson’s disease patients develop drug-induced involuntary 
movements (i.e., levodopa-induced dyskinesia). This clinical 
problem triggers the urgent need of identifying the circuit dys-
function resulting from dopamine loss and consequent levodo-
pa replacement. Mostly, the information flows into the striatum 
through glutamatergic cortical terminals innervating medium 
spiny neurons. At the same time, corticostriatal synapses are 
modulated by the nigrostriatal dopaminergic system implicated 
in action control and learning (Figure 1). Conversely, there are 
two main GABAergic output circuits controlling locomotion: 
the direct and indirect pathways. Interestingly, although both 
pathways are not anatomically separated, they express a differ-
ent set of GPCRs (Figure 2). Thus, the indirect-pathway neu-
rons selectively express dopamine D2 receptor (D2R) and A2AR, 
and the neurons from the direct pathway contain the dopamine 
D1 receptor and muscarinic acetylcholine M4 receptor. Impor-
tantly, intrinsic cholinergic interneurons, which represent only 
1% of total striatal neurons, play an important role in modulat-
ing GABAergic neuron excitability by tuning their response to 
glutamatergic inputs through postsynaptic muscarinic acetyl-
choline M1 receptor/muscarinic acetylcholine M4 receptor. In 
addition, at the presynaptic level cholinergic interneurons exert 
a tonic inhibitory effect over incoming information through 
muscarinic acetylcholine M2 receptor/muscarinic acetylcholine 
M4 receptor activation located on cortical and thalamic gluta-
matergic terminals.
Interestingly, many different A2AR containing heteromers has 
been described within the brain, thus establishing molecular 
and functional receptor-receptor interactions allowing neu-
rotransmission harmonization (Fuxe et al., 2014) (Figure 2). 
Precisely, in the dorsolateral striatum, the dopaminergic and 
adenosinergic transmission is tuned by D2R/A2AR heteromers. 
Indeed, the control of motor function by adenosine is based on 
the ability of A2AR to tightly control D2R function, both at the 
level of intracellular signaling as well as by an heteromer-de-
pendent A2AR-D2R negative allosteric modulation. Importantly, 
GPR37, through its chaperone-like activity, controls A2AR cell 
surface targeting in vivo, thus limiting the plasma membrane 
density and function of A2AR (Morató et al., 2017). Therefore, 
its heteromerization with GPR37 may sculpt the ability of A2AR 
to modulate D2R and therefore dopaminergic transmission. 
Indeed, GPR37 deletion prompts an enhanced A2AR membrane 
trafficking and response to adenosinergic drugs (Morató et al., 
2017, 2019). Thus, chronic blockade of A2AR induced a sensiti-
zation of locomotor activity, which is associated with elevated 
dopamine concentrations and synaptic changes in the striatum. 
These striatal plastic changes powerfully regulate basal ganglia 
circuitry by setting the gain on cortical and thalamic inputs, 
thus formatting motor function. Indeed, long-lasting alterations 
in striatal plasticity have been proposed to play a key role in 
movement disorders such as Parkinson’s disease, Huntington’s 
disease and dystonia. 
Interestingly, while long-term potentiation in the hippocam-
pus and LTD in the cerebellum are well established models 
of synaptic plasticity, the molecular mechanisms underlying 
striatal plasticity remain elusive. Eventually, the study of syn-
aptic plasticity in the striatum has been limited by the difficulty 
in triggering reliable, long-lasting long-term potentiation in 
striatal brain slices under physiological conditions. Certainly, 
the mechanisms governing LTD induction and expression vary 
across brain regions. Thus, in medium spiny neurons, low-fre-
quency stimulation of corticostriatal afferent fibers leads to a 
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different form of LTD (Ronesi and Lovinger, 2005). This form of 
striatal long-term synaptic plasticity involves glutamate and do-
pamine. Indeed, the best-studied form of striatal plasticity is the 
homosynaptic endocannabinoids (EC)-dependent LTD (eCB-
LTD) at glutamatergic synapses (Figure 2). Typically evoked 
by persistent low frequency stimulation, eCB-LTD relies in the 
activation of postsynaptic receptors couped to protein Gq/11 (i.e., 
metabotropic glutamate type 5 receptors) triggering phospho-
lipase C (PLC) activation and synthesis of ECs (2-arachido-
noyl glycerol and anandamide) which diffuses presynaptically 
to activate CB1 cannabinoid receptors and suppress synaptic 
transmission (i.e., lower glutamate release probability) (Figure 
2) (Gerdeman et al., 2002). Interestingly, eCB-LTD is observed 
mainly at glutamatergic synapses onto indirect-pathway me-
Figure 2 Indirect pathway striatal spiny module. 
The medium spiny neuron dendritic spine, the glutamatergic terminal and the dopaminergic terminal constitute the so-called striatal spiny mod-
ule (SSM). The segregation of DA and adenosine receptors within the two subtypes of medium spiny neurons suggests the existence of at least 
two subtypes of SSMs, which could be termed as enkephalin-SSM (i.e., indirect pathway) and dynorphin-SSM (i.e., direct pathway). Thus, while 
dynorphin-SSM predominantly express DA D1 receptor (D1R), enkephalin-SSM express DA D2 receptors (D2Rs) and A2ARs. The endocannabinoid 
(EC)-dependent long-term depression (LTD) model at enkephalin-SSM requieres activation of postsynaptic Gq/11-protein coupled receptors 
(i.e., metabotropic glutamate type 5 receptors (mGlu5Rs)) propmting ECs synthesis and release. Co-activation of postsynaptic D2R enhances ECs 
production. ECs activate presynaptic cannabinoid 1 receptor (CB1R) which induce LTD. GPR37, by modulating A2AR and D2R, play a key role 
balancing ECs production and thus LTD. Chronic A2AR antagonist treatment (i.e., SCH58261, 1 mg/kg per day, intraperitoneal administration, 10 
days) induced an increase of A2AR density in the striatum of wild-type and GPR37
-/- mice. Interestingly, under the same experimental conditions a 
reduction in striatal adenosine (Ado) levels and a potentiation of striatal LTD and locomotor sensitization was observed only in GPR37-/- mice (right 
panel). ATP: Adenosine triphosphate; cAMP: cyclic adenosine monophosphate; DA: dopamine; DAT: DA transporter; Glu: glutamate; LS: locomo-
tor sensitization.  
Figure 1 Striatal medium spiny neurons are 
modulated by corticostriatal and 
nigrostriatal neurons. 
Collateral axons from glutamatergic cortical 
neurons (pink traces) establish synapses with 
the head of dendritic spines of medium spiny 
neurons, the most common neuron in the stri-
atum. Simultaneously, dopaminergic afferents 
from the substantia nigra pars compacta (green 
traces) make synaptic contact with the neck of 
the medium spiny neuron dendritic spine.  
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dium spiny neurons (Kreitzer and Malenka, 2008), precisely 
where D2R/A2AR heteromers are expressed and interact with 
metabotropic glutamate type 5 receptors (Figure 2) (Cabello 
et al., 2009). Furthermore, presynaptic A2AR are powerful reg-
ulator of CB1 receptor-mediated synaptic depression in corti-
costriatal synapses of the dorsal striatum and they also control 
metabotropic glutamate type 5 receptor function at these same 
synapses (Cunha, 2016). Likewise, post-synaptic A2AR also con-
trol these same receptor systems at postsynaptic compartments, 
as well as D2R. This prompts several still unanswsered questions 
on the fine-tuning of LTD in the indirect-pathway by adenosine 
and dopamine, such as: i) how does A2AR blockade enhances 
LTD? ii) why does eCB-LTD requires D2R activation? Indeed, 
dopamine depletion, D2R antagonists and D2R deletion prevent 
striatal LTD induction. 
Although prosaposin has been postulated as ligand, GPR37 
still is an orphan GPCR (i.e., not yet been linked to endogenous 
ligands). In addition, there is a lack of highly selective GPCR37 
ligands allowing ex vivo and in vivo functional studies, thus 
currently research efforts are concentrated in GPR37-based 
drug discovery. Hence, experiments in mice lacking GPR37 are 
unique in providing some hints about its function. Also, the 
assessment of the GPR37 interactome revealing GPCR partners 
(i.e., A2AR and D2R) aid to understand the biological relevance 
of this orphan receptor particularly in the central nervous sys-
tem (Sokolina et al., 2017). Indeed, since GPR37 deletion does 
not affect striatal LTD and hippocampal LTD (Lopes et al., 
2015; Morató et al., 2019), we assume that GPR37 function per 
se do not play a role in synaptic plasticity. However, the pro-
teomic studies revealing the ability of GPR37 to heteromerize 
with A2AR suggested that this orphan receptor may function in 
a ligand-independent manner (i.e., chaperone-like) modulating 
A2AR function (i.e., repressor) in different brain regions (i.e., 
striatum and hippocampus). It is important to highlight that 
GPR37-dependent physiological effects (i.e., increased striatal 
LTD and locomotor sensitization) were observed only upon 
chronic A2AR blockade, thus reinforcing the role of GPR37 in 
long-term neuroadaptations mediated by the adenosinergic sys-
tem. Also, these results consolidate the idea that A2AR-mediated 
control of motor sensitization is a consequence of the ability of 
A2AR to control corticostriatal plasticity. This selective impact of 
GPR37 ablation on long-term adaptive changes of A2AR func-
tion may be of particular relevance for striatal-related neurode-
generative diseases. In fact, there is an abnormal over function 
of A2AR coupled with perturbed corticostriatal plasticity at the 
onset of striatal-related neurodegenerative diseases, such as Par-
kinson’s or Huntington’s diseases (Cunha, 2016); this prompts 
considering a prominent role for GPR37 at the onset of these 
disorders, through its ability to control A2AR trafficking to the 
plasma membrane.
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